Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT01976338 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

283

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Edema Secondary to Branch Retinal Vein Occlusion

Interventions

DRUG: Ranibizumab 0.5 mg
OTHER: Sham injection

Sponsor

Novartis Pharmaceuticals